Ph3 study assessing the efficacy of Immunotherapy in participants with NSCLC SUNRAY-02
Phase III Clinical Trial
A Phase 3 Multicenter Double-Blind Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant Non-Small Cell Lung Cancer - SUNRAY-02 (J3M-MC-JZQH)
Participating Locations